
ABOUT AJINOMOTO BIO-PHARMA SERVICES
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization, with sites in Belgium, United States, Japan and India, providing comprehensive process development services, cGMP manufacturing and drug product fill finish services of small molecule and biologic APIs and intermediates. We offer a broad range of innovative platforms and capabilities to rapidly scale from clinical and pilot programs to commercial quantities, including: Corynex protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet our clients’ needs.
Ajinomoto Bio-Pharma Services offers a range capabilities through its facilities around the world. Our facilities in Belgium, Japan, and India focus on conventional small molecule API and intermediate production. The focus at our California, USA facility is on large molecule and ADC manufacturing and aseptic fill finish services. Our Osaka, Japan facilities focus on oligonucleotide synthesis.
Our expertise and extensive knowledge of international requirements help assure your product will meet the highest possible quality standards. Our goal is to deliver quality product and personalized service, while providing flexibility and guidance to help our clients achieve their goals in a timely and efficient, cost-effective manner.
Ajinomoto Bio-Pharma Services is a member of the Ajinomoto Group companies, a global company focused on the research, development, and manufacture of high quality products for the pharmaceutical, specialty chemical, nutraceutical, sports nutrition, and health & beauty industries, as well as food seasonings and consumer food products.
VIDEOS AND WEBINARS
-
October 2022 Outsourced Pharma Capacity Update presenter Ajinomoto Bio-Pharma Services has been actively producing high quality APIs and intermediates for the pharmaceutical industry for more than 40 years. In this video, learn about their capabilities and available capacity as well as how their experienced and knowledgeable chemists and engineers provide customers the ability to rapidly scale from pilot to commercial product.
-
Ajinomoto Bio-Pharma Services highlights the new high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA. They discuss their capabilities and capacity in clinical and commercial manufacturing, including automated visual inspection/semi-automated visual inspection.
-
Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical contract development and manufacturing services. The company has expanded current capacity as well as component flexibility with the addition of a high speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego, CA. In this presentation, Aji Bio-Pharma will discuss this expanded flexible aseptic fill finish capacity.
-
Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. In this presentation, Aji Bio-Pharma will discuss the capacity, expertise, and equipment available for drug substance and plasmid manufacturing for gene therapies.
-
Whether you are in the beginning research stages or ready to take your product to market, our scalable, high quality, and custom oligo and peptide solutions provide the quantities you need using the most reliable, robust, and cost-effective process available.
-
The production of your biotherapeutic deserves the reliability and peace of mind that only a trusted and experienced microbial fermentation partner can provide. Ajinomoto Bio-Pharma Services is a recognized leader in recombinant protein, plasmid DNA, and critical raw material manufacturing for vaccine and gene therapy applications.
-
Consolidate your supply chain by having your packaging integrated with your product manufacturing.
-
We offer a unique range of formulation and aseptic filling in vials, prefilled syringes or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.
-
Whether it's a liquid or lyophilized product, we provide capacity, quality, and expertise to ensure a stable supply of your promising therapeutics.
-
The HANU, a new photo-flow reactor, provides better process control, less risk in hazardous chemistry, less solvent use, and is better for the environment.
-
Our fully contained and integrated OPTIMA line utilizes scan isolated barrier technology to ensure the required sterility for fill finish while offering flexibility to meet your cGMP, clinical, and commercial drug product manufacturing needs.
-
Ajinomoto Bio-Pharma Services is a leader in aseptic filling, offering a wide range of capabilities for vials with our OPTIMA 7000 fill line. The OPTIMA VFVM 7000 safely processes various types and classes of biopharmaceutical products in 2 mL to 100 mL sizes.
-
We offer a unique range of formulation and aseptic filling in vials, prefilled syringes, or cartridges to address production needs that span from small early stage clinical products to larger scale commercial products.
-
We provide therapeutic drug development and manufacturing services to biotechnology and pharmaceutical companies worldwide. We have the power to make your therapeutic vision a reality — from pre-clinical through commercial production.
-
Examine the development and manufacturing expertise required to seamlessly transition from research to commercial stages to ensure smooth operation from early to late stage development.
-
Experts share the necessary development and manufacturing considerations for a smooth tech transfer, exploring these challenges in depth, and discuss the questions you should be asking your manufacturer.
-
With an increased demand for plasmids for targeted gene therapeutic delivery, partnering with a CDMO equipped with the capacity, expertise and equipment for plasmid DNA production is critical.
-
An industry expert shares about sustainable Oligo manufacturing approaches that can save time, cost, and resources – while improving purity, quality, and scalability of these promising therapeutics.
-
Tom Evans, MS, CMMS discusses the planning, resources, and capabilities necessary to effectively produce a client’s highly potent active pharmaceutical ingredient (HPAPI) therapeutic.
-
A clear increase in continuous flow processes has emerged over the past decade, thanks to the commercialization of preparative flow reactor units.
CONTACT INFORMATION
Ajinomoto Bio-Pharma Services
11040 Roselle Street
San Diego, CA 92121
UNITED STATES
Phone: 858-882-0123
Fax: 858-839-7329
SERVICES
BROCHURES
- Fill Finish Capabilities: COVID-19
- Large Molecule Manufacturing
- AJILITY™ Platform - Streamline Your Drug Product Manufacturing Program
- Drug Product Capabilities: Aseptic Fill Finish
- Oligos And Peptides - A Seamless Supply From Research To Commercial Scale
- Possibilities For Streamlining Drug Product Manufacturing
- We Have The Power To Make
- Ajinomoto Bio-Pharma Services Simplified ADC Supply Chain
- Drug Product Manufacturing: Aseptic Fill Finish
FEATURED ARTICLES
- Ajinomoto And Exelixis Enter Into A License Agreement To Discover And Develop Novel Antibody-Drug Conjugates For The Treatment Of Cancer
- Managing Outsourcing For Complex Formulations
- Diving Into The Intricacies Of An Approach To Continuous Flow
- Q&A: Plasmid Manufacturing For Gene Therapies
- Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity With New Multi-Purpose Fill Suite
- Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement With AstraZeneca To Include Drug Product Manufacturing
- Ajinomoto Co., Inc. And Bright Peak Therapeutics Inc. Enter Into A Research Collaboration And License Agreement To Create Novel Immunocytokines
- Ajinomoto Bio-Pharma Services And Humanigen Expand Manufacturing Agreement To Support Fill Finish For Investigational COVID-19 Therapeutic, Lenzilumab, Nearing Completion Of Phase 3 Study
- Ajinomoto Bio-Pharma Services And Revance Therapeutics Announce Manufacturing Agreement For Supply Of DaxibotulinumtoxinA For Injection
- First Commercial Drug Manufactured Via Ajinomoto Bio-Pharma Services’ AJIPHASE Technology Receives FDA Approval
- Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform For Drug Product Manufacturing
- Oligonucleotide Therapeutics: Partnering With The Right CDMO
- Ajinomoto Bio-Pharma Services Completes Acquisition Of Granules OmniChem Joint Venture In India
- Ajinomoto Bio-Pharma Services Signs Manufacturing Agreement with Humanigen for Lenzilumab, Currently in FDA-Approved Phase III Study for COVID-19
- Ajinomoto Bio-Pharma Services Announces Manufacturing Partnership With CytoDyn For Drug Product Used In COVID-19 Clinical Trials
- From Research To Commercial: A Seamless Supply Of Oligonucleotides
- Are You Protecting Your Employees During HPAPI Manufacturing?
- Strategy For ADC Synthesis Using Site-Specific Chemical Conjugation
- Continuous Flow Manufacturing Of Pharmaceutical Ingredients
- Critical Factors For Large Molecule Fill/Finish Manufacturing